NEGACEF IM/IV Infusion
Ceftazidime
500mg
Julphar (Gulf Pharmaceutical Industries)
| Pack size | 1 Vial (Dry) |
|---|---|
| Dispensing mode | POM |
| Source | UAE |
| Agent | JULPHAR |
| Retail Price | 21.00 AED |
Indications
NEGACEF IM/IV Infusion is used for:
Pneumonia, Cystic fibrosis, Bacterial septicemia, Meningitis, Peritonitis, Skin and Skin-Structure Infections, Endometritis, Pelvic cellulitis, Respiratory tract infections, Urinary tract infections, Febrile neutropenia, Melioidosis, Bone and Joint Infections,G ynecologic Infections, Biliary tract infections, Endophthalmitis
Adult Dose
Bone & Joint Infections
2 g IV q12hr
Gynecologic & Intra-abdominal Infections, Meningitis, Complicated Pneumonia, Life-Threatening Infections
2 g IV q8hr
Pulmonary Infections
Infections caused by Pseudomonas spp in patients with cystic fibrosis who have healthy renal function
30-50 mg/kg IV q8hr; not to exceed 6 g/day
Uncomplicated Pneumonia
0.5-1 g IV q8hr
Mild Skin/Skin Structure Infections
0.5-1 g IV or IM q8hr
Urinary Tract Infections
Complicated: 500 mg IV or IM q8-12hr
Uncomplicated: 250 mg IV or IM q12hr
Elderly: >80 yr Max: 3 g daily.
Child Dose
Child: IV, IM 90–150 mg/kg/day q8h
IV 200–300 mg/kg/day for serious Pseudomonas infection (max 8–12 g/day) q8h
Renal Dose
Renal impairment: Loading dose: 1 g; maintenance doses based on CrCl. May need to increase doses by 50% in severe infections. Peritoneal dialysis: Loading dose is followed by 500 mg every 24 hr; may add ceftazidime to the dialysis fluid (usually 125-250 mg for 2 litres of dialysis fluid). Haemodialysis: Admin loading dose then 0.5-1 g after each dialysis period.
CrCl (ml/min)
31-50 1 g every 12 hr.
16-30 1 g every 24 hr.
6-15 500 mg every 24 hr.
<5 500 mg every 48 hr.
Administration
IV/IM Administration
IV
Direct injection: Inject over 3-5 minutes directly into vein or through tubing of running compatible infusion solution
Infusion: Infuse intermittently over 15-30 minutes
IM
Inject deeply
Contra Indications
Hypersensitivity to cephalosporins.
Precautions
History of penicillin allergy; severe renal impairment; pregnancy, lactation.
Lactation: Drug excreted in breast milk; use with caution
Pregnancy-Lactation
Pregnancy category: B
Lactation: Drug excreted in breast milk; use with caution
Interactions
May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
Adverse Effects
Side effects of Ceftazidime :
1-10%
Transient increases in transaminases (3-9%), Eosinophilia (<7%), Diarrhea (<2%), Immune hypersensitivity reaction (2%), Phlebitis (<2%), Rash (maculopapular or erythematous) (2%), Thrombocytosis (2%), Injection site pain (1%)
<1%
Abdominal pain, Agranulocytosis, Angioedema, Asterixis, Coma, Dizziness, Encephalopathy, Fever, Hallucinations, Increased serum concentrations of bilirubin, Leukopenia, Lymphocytosis, Metallic taste, Myoclonia, Nausea or vomiting, Neuromuscular excitability, Neutropenia, Paresthesia, Photosensitivity, Pruritus, Seizures, Thrombocytopenia, Transient increases in blood urea nitrogen (BUN) or serum creatinine, Urticaria
Potentially Fatal: Anaphylactic reactions, nephrotoxicity, pseudomembranous colitis.
Mechanism of Action
Ceftazidime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Note
NEGACEF IM/IV 500mg Infusion manufactured by Julphar (Gulf Pharmaceutical Industries). Its generic name is Ceftazidime. NEGACEF IM/IV is availble in United Arab Emirates.
Farmaco UAE drug index information on NEGACEF IM/IV Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.